Prescription Drug Price Transparency
Public Interest Drug Lists

The Minnesota Legislature expanded the Minnesota Prescription Drug Price Transparency Act in 2023 to include reporting from drug manufacturers, pharmacy benefit managers, wholesalers, and pharmacies on drugs of substantial public interest. The Minnesota Department of Health (MDH) is responsible for producing and publicly posting quarterly lists of the prescription drugs requiring reporting. 

For each reporting cycle, MDH releases the list of drugs that establish the respective reporting requirement and notifies reporting entities 30 or more days after the release date. From the date of notification, reporting entities have a 60-day reporting period, during which the required data must be submitted. 

Released lists

• Insulin: List of Drugs of Substantial Public Interest—March 2025 (Excel)
  • Insulin: List Methodology for Drugs of Substantial Public Interest Reporting—March 2025 (PDF)
  • Date MDH posted list: 03/12/25
  • Date MDH sent notifications: 04/21/25
  • Deadline for reporting: 06/20/25
  • Date range for data: 04/01/24 through 03/31/2025
• List of Drugs of Substantial Public Interest—June 2024 (Excel)
  • List Methodology for Drugs of Substantial Public Interest Reporting—June 2024 (PDF)
  • Date MDH posted list: 6/26/24
  • Date MDH sent notifications: 08/01/24
  • Deadline for reporting: 09/30/24
  • Date range for data: 08/01/23 through 07/31/24

Future lists

MDH will continue to seek public input for future lists using various strategies including interviews with payers, consulting experts, and engaging patients. MDH expects to adjust the release of subsequent lists to ensure no more than one list is released quarterly. 

The Minnesota Department of Health (MDH) wants to hear from you!

Have prescription drug prices impacted your health care? What do you think is creating affordability challenges for patients? What drugs – and their prices – have a substantial public interest and would benefit from pricing transparency?

By completing the Public Input on Prescription Drug Price Transparency in Minnesota form, you can: share your experiences and suggest where you think MDH should focus its drug price transparency work.